Please use this identifier to cite or link to this item:
|Title:||5-Carboxamidotryptamine attenuates the development of deoxycorticosterone acetate-salt hypertension in rats|
|Keywords:||(Chronic i.v. infusion)|
DOCA-salt (deoxycorticosterone acetate-salt) hypertensive rat
|Citation:||Balasubramaniam, G., Lee, H.S., Mah, S.C. (1995). 5-Carboxamidotryptamine attenuates the development of deoxycorticosterone acetate-salt hypertension in rats. European Journal of Pharmacology 276 (1-2) : 183-190. ScholarBank@NUS Repository. https://doi.org/10.1016/0014-2999(95)00030-O|
|Abstract:||The effect of chronic i.v. infusion of the 5-HT1 receptor agonist, 5-carboxamidotryptamine (5-CT), was evaluated during the development of deoxycorticosterone acetate-salt (DOCA-salt) hypertension in rats over 4 weeks. Vehicle-treated ((n = 10) Sprague-Dawley rats given DOCA (100 mg/kg, s.c.) and 1% saline as drinking fluid developed hypertension with systolic blood pressure reaching 194.6 ± 8.99 mmHg at 27 days. In DOCA-salt rats treated with 5-CT infusions (15.0 μg/kg per day, n = 10) for 4 weeks via osmotic minipumps, systolic blood pressure was significantly lower by 41.7 mm Hg at day 27 when compared to vehicle-treated DOCA-salt rats. Systolic blood pressure values on day 27 in 5-CT-treated DOCA-salt rats were however greater than those in vehicle-treated control rats which were not given DOCA. Systolic blood pressure in 5-CT-treated DOCA-salt rats was significantly lower by day 7 compared to vehicle-treated DOCA-salt rats and remained lowered for the rest of the observation period. Heart rate was significantly greater in 5-CT-treated DOCA-salt rats on day 7 when compared to vehicle-treated DOCA-salt rats. Baroreflex sensitivity on day 28 was significantly greater in 5-CT-treated DOCA-salt rats as compared to vehicle-treated DOCA-salt rats. On day 28, hypotensive responses to hexamethonium (20 mg/kg) in 5-CT-treated DOCA-salt rats were markedly reduced compared to those in vehicle-treated DOCA-salt rats. The data suggest that chronic administration of 5-CT attenuates the development of DOCA-salt hypertension in rats with concomitant attenuation of the dampening of baroreffex sensitivity seen during the development of hypertension. The results also suggest a peripheral sympathoinhibitory action of 5-CT in addition to the known peripheral vasodilatation via 5-HT1 receptors.|
|Source Title:||European Journal of Pharmacology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 13, 2019
WEB OF SCIENCETM
checked on Feb 13, 2019
checked on Feb 9, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.